Previous 10 | Next 10 |
2023-11-29 16:04:27 ET More on Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals: A High-Risk, High-Reward Bet Arrowhead Pharmaceuticals Q4 2023 Earnings Preview GSK inks $1B deal to obtain rights to hepatitis B drug from J&J Seeking Alpha’s Quan...
- Conference Call and Webcast Today, November 29, 2023, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2023. The company is hosting a conference call today, November 29, 2023, at 4:30 p.m. ET to disc...
Addex Therapeutics Ltd (ADXN) is expected to report $-4 for Q3 2023 Eco Wave Power Global AB (publ) (WAVE) is expected to report for quarter end 2023-09-30 AmeraMex International, Inc. (AMMX) is expected to report for Q3 2023 iClick Interactive Asia Group Limited (ICLK) is expected to...
Arrowhead Pharmaceuticals Inc. (ARWR) is expected to report $-0.7 for Q4 2023
2023-11-28 17:35:34 ET More on Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals: A High-Risk, High-Reward Bet GSK inks $1B deal to obtain rights to hepatitis B drug from J&J Ionis late-stage rare disease data fails to impress Bernstein Seeking Alpha...
2023-11-28 17:35:21 ET Major earnings expected after the bell on Wednesday include: Salesforce ( CRM ) Snowflake ( SNOW ) Okta ( OKTA ) Synopsys ( SNPS ) Pure Storage ( PSTG ) For further details see: Notable earnings after Wednesday's close
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-DM1, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for type 1 myotonic dy...
2023-11-26 08:00:00 ET Related stories Workday Earnings Preview: AI And ML Are Promising But Hard To Quantify The Result Splunk: Why This Inflection Investor Is Calling It A Day Here CrowdStrike: Poised To Deliver Another Resilient Quarter, Although Stock Looks Overb...
2023-11-22 09:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference on November 30, 2023, at 1:00 p.m. ET. A webcast of the presentation may be accessed on the Events and Presen...
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
Arrowhead Pharmaceuticals Inc. Website:
– Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease – CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84 th Scientific Sessions, which were held J...
2024-06-05 05:00:08 ET Andrea Tan from Goldman Sachs issued a price target of $31.00 for ARWR on 2024-06-05 02:24:00. The adjusted price target was set to $31.00. At the time of the announcement, ARWR was trading at $25.29. The overall price target consensus is at $60.00...